Oppenheimer analyst Jay Olson lowered the firm’s price target on Enanta (ENTA) to $14 from $16 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 results with quarterly HCV royalties of $14.6M, OpEx of $44.5M, and $248.2M cash expected to provide runway into 2027. Enanta remains on track to report topline results from Phase 2 RSVPEDs study of zelicapavir in infants and children with RSV in December.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: